News for Avecho Biotechnology Limited (AVE.AX)

Avecho Biotechnology (ASX: AVE) has received a maiden payment of approximately $4.7 million (US$3m) from international generic and biosimilar medicines

PR NewswireMELBOURNE, Australia, March 3, 2025 Highlights:Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for

Avecho Biotechnology (ASX: AVE) has signed an exclusive 10-year development and licensing agreement with Swiss generic pharmaceuticals developer Sandoz

**media[467153]**

Avecho Biotechnology (ASX: AVE) has embarked on a journey to treat insomnia, a prevalent sleep disorder, through a Phase III clinical trial.

Long-term efforts by Avecho Biotechnology (ASX: AVE) to further the clinical and commercial potential of its TPM (tocopheryl phosphate mixture) enhanced products gained traction during the three months to end June.

Avecho Biotechnology (ASX:AVE) has passed a "crucial" two-year stability milestone for its TPM-enhanced cannabidiol (CBD) soft-gel capsule.

Avecho Biotechnology (ASX:AVE) has completed the development of its first-generation proprietary TPM gummies containing cannabinoids.

The ASX was tracking lower in midday trade today following news Australia’s economy grew point two per cent in the first three months of this year.

The US Patent and Trade Marks Office has allowed Avecho Biotechnology (ASX: AVE) a new patent application directed to an optimised manufacturing process for its drug delivery system tocopheryl phosphate mixture (TPM).

After two positive weeks the Australian market ended the week down 1.7%, despite a bit of a late rally with a 0.2% rise on Friday.

Avecho Biotechnology (ASX:AVE) has signed a licensing and development agreement with the Arthur Group to develop a series of cancer treatments.

Avecho Biotechnology (ASX: AVE) has signed an agreement with Arthur Group LLC for the licensing and development of a series of leading cancer drugs using tocopherol phosphate mixture (or TPM) to replace conventional adverse solvents or surfactants.

Melbourne-based Avecho Biotechnology (ASX: AVE) is seeking to raise $11 million to fund a pivotal clinical trial evaluating the use of its cannabinoid (CBD) soft-gel capsule to treat insomnia.

Cannabis: Top pot analysts forecast the Asian market could grow by at least 10 times to around US$120 million by 2026.

On Stockhead, Gregor unleashes over the future of Forex, Scott and Nadine get all ASX healthy. The Badman goes back to when crypto was young

The Westpac-Melbourne Institute predicts a sustained below trend outlook for the Australian economy in 2023.

The Grinch is also making an appearance on global and Aussie markets this week before Christmas with the ASX continuing its downwards trend.

WA Resources among ASX stocks to hit a 52-week high in October as markets rally in a positive sign of recovery.